**Appendix Table D4. Study design characteristics**

| **Author, Year****PMID****Country****Study name** | **Study design** | **Multicenter (yes/no)** | **Recruitment method** | **Sampling population** | **Enrollment period** | **Mean or median (state which follow up duration)** | **Setting** | **A Priori power analysis performed? (if yes, was accrual 80% of target or higher)** | **Funding** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Collet, 200919108880FranceAFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry | Prospective observational, registry based study | YES | Convenience sample of patients from a registry of AMI in patients <45 yr, on clopidogrel for ≥1 mo, with available genotyping information | Young patients with AMI (STE MI or NSTE MI)  | The registry covers the period from April, 1996 to April, 2008; patients entered before 1999 (year when clopidogrel became available in the study population) were excluded | Median clopidogrel exposure = 1.07 yr (IQR = 0.28, 3.0)Maximum FU = 8 yrMean followup = 2.7 yr for CYP2C19 \*2 carriers; 2.9 yr for CYP2C19 non-carriersMean followup = 2.84 yr | Patients were survivors of AMI enrolled in a multicenter registry; followup was on an outpatient basis | Not performed | Non-industry |
| Fontana, 200817681590Switzerland | Prospective observational study | YES | Consecutive patients who received PCI with stenting in a single center | Patients undergoing PCI with stent placement | NR | Measurements after ≥15 d under clopidogrel (median FU = 19 d; IQR = 15-47) | Inpatient for PCI; outpatient for followup after discharge | Power calculations performed; enrolled 81 patients out of a planned sample size of 100  | Non-industry only |
| Giusti, 200718004210ItalyNR | Observational study, prospective (measurements 24 h after PCI) | NO | Consecutive patients | Patients with ACS, undergoing primary PCI | NR | 24 h post PCI | Inpatient | no (posthoc only) | Non-industry only |
| Giusti, 200919268736ItalyRECLOSE study(Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis) | Prospective observational study of patients enrolled in the RECLOSE study in a single center  | NO(single center recruitment for this study) | Consecutive patients consenting to genetic study identified from the RECLOSE study population | Patients with ACS or CAD undergoing PCI with stenting | July 2005 to August 2006[recruitment period of the RECLOSE study; information from pmid = 17572245] | 6 months(unclear what metric; from the KM curves implied maximum FU) | In hospital (PCI) | Not performed | Non-industry only |
| Gladding, 200919926050New ZealandNR | Prospective “open label dose escalation study with molecular randomization” | No | NR | Patients who had undergone PCI >2 weeks previously and were on clopidogrel | NR | Total 7 days | Inpatient, with outpatient followup after the inpatient procedure | Yes (“~90%”) | NR(except “genotyping” was “supplied” by AutoGenomics, which is the affiliation of one of the authors) |
| Jinnai, 200919531897JapanPartly industry funded | Prospective | Unclear | Convenience sample | Patients scheduled for PCI | NR | Maximum 28 days; results reported only up to 48 hours | In-patient; patients undergoing elective PCI | Not performed  | Partly industry funded |
| Mega, 200919106084MultinationalGenetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction] | Prospective cohort study (genetics substudy of RCT, only one of the randomized arms included) | YES | Sub study of RCT | Patients with ACS (STE MI, NSTE MI ,UA) planned for PCI | 2004-2007 | 15 months | Inpatient  | Not performed  | Industry funding |
| Shuldiner, 200919706858USASinai Hospital of Baltimore Study | Retrospective, based on medical records (based on followup procedures) | NO | Convenience | CAD patients undergoing non-emergent PCI | January 2004–May 2007 | 12 months post-PCI | In-patient in a single catheterization laboratory (non-emergent PCI) | Not performed | Non-industry only |
| Sibbing, 200919193675GermanyNR | Prospective observational study | NO | Convenience sample; patients participating in several randomized clinical trials of abciximab | CAD patients undergoing PCI | May 2000–December 2005 | Complete followup to 30 days | Inpatient for PCI, outpatient followup for the duration of the study followup. Patients with cardiac symptoms were seen in the outpatient clinic for further investigation | Not performed [power analysis was performed post hoc, based on the observed effect size] | Non-industry only(several authors with COI) |
| Sibbing, 201020083681GermanyPart of a prospective study of the Multiplate analyzer | Observational study, prospective | NO | Consecutive patients recruited from a study of the Multiplate analyzer | Patients with CAD with planned DES implantation; patients were eligible regardless of clinical presentation (stable angina, UA, STE MI, or NSTE MI). | February 2007–April 2008 | 30 d ±7 days (all outcomes adjudicated at that time-point by phone interview with outpatient clinic visits for those reporting cardiac symptoms) | Inpatient for elective PCI (patients were hospitalized for ≥2 days); patients were the interviewed by phone (outpatient) and those reporting symptoms were examined in the outpatient clinic (for clinical, EKG, and laboratory checkup) | Not performed | Partly industry supported (material provided by manufacturer of the Multiplate analyzer, which was used here as a reference standard) |
| Varenhorst, 200919429918SwedenNR | Prospective observational study (genetics sub study of RCT comparing antiplatelet regimens) | Yes(2 centers in Sweden) | Sub study of RCT | Patients with CAD (~98% had received PCI before inclusion in the parent trial) | April 2006 to December 2006[for the parent study] | Maximum followup 29 d±3 d (last measurements obtained) | Outpatients who had regular visits for reactivity measurements | Not performed (for the genetic sub-study) | Industry funded |
| Frere, 200818394438FranceNR | Prospective | NO | Consecutive patients | NSTE ACS patients undergoing angiography | 2004–2006 | ≥12 h after loading | Inpatient | NO | NR |
| Frere, 200919496924FrancePart of larger observational study | Retrospective | NO | Convenience | NSTE ACS patients undergoing angiography | 2004–2006 | NR(measurements appear to have been obtained after the clopidogrel loading dose) | In-patient, single cardiology department | Not performed | NR(authors’ stated that there was “no conflict of interest”) |
| Bonello-Palot, 200919932784FranceNR | Prospective observational study | YES | Convenience sample | Patients undergoing percutaneous coronary intervention (PCI) for ACS; Patients with acute coronary syndromes (ACS) | Aug 2007–Mar 2008 | NR (patients were followed up from admission till the PCI was performed) | Inpatient  | Not performed | Partly Industry |
| Harmsze 201019934793NetherlandsNR | Prospective observational cohort | NO | Consecutive patients | Patients undergoing percutaneous coronary intervention (PCI) for ACS | NR | NR | Inpatient | Not performed | Partly Industry |
| Trenk 200818482659GermanyEXCELSIOR (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantationon Clinical Event Rate) | Prospective observational study  | NO | Substudy of the EXCELSIOR prospective study | CAD patients undergoing elective PCI with stent implantation  | NR | 30 day follow up for all patients, and 12 month follow up for 795 patients (99.1%) | followup after intervention | no (power analysis for the parent study) | Non-industry only |
| Tantry, 201021079055Multicountry- North America and EuropeGenetic substudy of ONSET/OFFSET and RESPOND | RESPOND and ONSET/OFFSET were randomized, double-blind, double-dummy, multicenter studies. RESPOND was crossover; ONSET/OFFSET was parallel-group (prospective) | YES | Sub study of RCT  | Adults with stable coronary artery disease receiving aspirin who consented to genotyping  | RESPOND, May 19, 2008, to March 25, 2009ONSET/OFFSET, October 2007 toMarch 2009 | 2-6 weeks | Outpatient | For both RESPOND and ONSET/OFFSET,YES[YES]Not done for genetic substudy (they took whoever consented) | All industry |
| Wallentin, 201020801498Multinational (43 countries in North America, South America, Europe, Asia, Australia)PLATO | Prospective observational study | YES | Sub study of RCT | ACS patients with <80% undergoing PCI | October 2006 through July 2008 | Median, 277 days | Inpatient | NO (not prospectively powered and had to be based on the maximum number of patients consenting to provide a blood sample for genetic analysis) | All Industry |
| Hochholzer, 201020510210GermanyEXCELSIOR | Prospective cohort  | No  | Unclear | Patientsundergoing PCI with stenting | NR | 30 days to 6 months  | inpatient | Not performed | NR |
| Jeong 201020650435KoreaACCEL-DOUBLE | Cohort  | No  | Sub study of RCT | Patients with CAD undergoing PCI | Jan 2008-June 2009 | ≥1 mo | inpatient  | it was estimated that a total of 95 patients (57 carriers and 38 noncarriers of the *CYP2C19* variant allele) would be required to provide a power of 90% to detect a statistically significant difference with a 2-sided alpha-level of 0.05. | NR |
| Barker, 201020965456USANR | Prospective cohort  | No  | Selected CAD patients; unclear methods | CAD patients had clopidogrel for >7 days or high OTR | NR | Mean 8 days  | Unclear  | Yes, 90% | Non-industry |
| Bonello, 201020708365FranceNR | Prospective cohort  | Yes  | Selected sample of Patients with PCI | Patients with PCI | Jan 2009-Jan 2010 | NR | Inpatient | Not performed | NR |
| Gurbel 201121392617USANR | Cohort  | No  | Unclear | Patients had established coronary artery disease (CAD) and were on aspirin (81-325 mg/d) therapy for a minimum of 2 weeks were studied (N = 261). | NR | NR | Outpatient | Yes. Given the frequency of the \*2 allele in the population, to determine a 20% absolute difference in the prevalence of HPR between these 2 groups, a sample size of 105 patients was required with an a = .05 and power of 80%. | Non-industry |
| Hwang 201121075428South KoreaNR | Cohort  | No  | Consecutive patients  | CAD patients undergoing elective PCI with stent implantation | Jan 2008-March 2009 | NR | Inpatients from Department of Cardiology of the Gyeongsang National University Hospital  | Not performed | Non-industry |
| Kang, 201020724801KoreaNR | Cohort  | No  | Consecutive  | CAD patients with elective stent implantation  | July 2008-June 2009 | NR | Hospital  | Not performed | Non-industry |
| Liu 201021163112ChinaNR | Cohort  | No  | Consecutive  | Patients were admitted for elective coronary intervention with symptomatic stable CAD.  | Oct 2006-Sep 2007  | 12 months minimum  | Hospital  | Not performed | NR |
| Maeda, 201021178986JapanNR | Cohort  | No  | NR | CAD | NR | >4 weeks | Unclear | Not performed | NR |
| Malek, 201020924183PolandNR | Cohort  | No  | Consecutive  | AMI with and without ST-elevation, PCI with stenting was attempted.  | 2005-2005 | 4 years  | Hospital  | Not performed | Non-industry |
| Simon 201121262992FranceFAST-MI | Prospective observational study (registry-based) | Yes | Consecutive | AMI patients undergoing PCI (<80%)  | 2005-2006 | 1 year  | Inpatient ( from ICU)  | Not performed | Partly industry |
| Simon 201119106083FranceFAST-MI | Prospective observational study (registry-based) | Yes | Consecutive | AMI patients undergoing PCI (<80%)  | 2005-2006 | 1 year  | Inpatient ( from ICU)  | Not performed | Partly industry |
| Yamamoto 201121168310JapanNR | cohort | No | Consecutive  | CAD undergoing angiography (and PCI when needed); PCI(for those assessed for clinical outcomes) | NR | 340 days | Inpatient | Not performed | NR |
| Park 201121345843KoreaCILON-T | Randomized trial  | yes | Sub study of RCT | CAD patients undergoing PCI with stenting | 2006-2009 | 6 months | Inpatient | Yes 18 non-carriers and 11 carriers of CYP2C19-LOF would be needed to provide a power of 95% to detect a statistically significant difference between groups with a two-sided a-level of 0.05. | Non-industry |
| Tiroch, 201020826260GermanyNR | Cohort  | No  | Consecutive  | AMI patients with >90% of them undergoing PCI with BMS placement  | 2005-2008 | 1 year  | Inpatients in a Hospital  | yes80% | NR |
| Sorich, 201020492467707 sites in 30 countriesSubstudy of TRITON-TIMI 38 | Substudy of RCT | Yes  | Selected sample  | PCI | November 2004 and January 2007. | 6 to 15 months. | Hospital (inpatient) | Not performed | Industry |
| Sibbing, 201020492469GermanyNR | Cohort  | No  | Consecutive  | Stable CAD patients undergoing angiography | Aug 2007 to Sep 2008 | NR | Inpatients in a Hospital  | Not performed | NR [Speaker fee from industry by first author] |
| Sawada, 201021099121JapanNR | Cohort  | No  | NR | PCI | Jan 2008-Jan 2010 | 243.8±88.1 daysMedian 223.5 days, range 7–546 days  | In patients at Kobe University Hospital  | Not performed | NR |
| Pare, 201020979470MultinationalCURE | Prospective cohort study | Yes  | Sub-study of RCT | Patients with ACS-NSTE  | 1998–2000 | 3.6 years | Inpatient  | NO | Industry |
| Pare, 201020979470MultinationalACTIVE-A | Prospective cohort study | Yes | Sub-study of RCT | Patients with AFIB  | 2000–2006 | 3–12 months  | Outpatient  | NO | Industry |
| Mega, 201020801494707 sites in 30 countriesTRITON-TIMI 38 | Prospective cohort study  | Yes  | Sub study of RCT | ACS | November 2004 and January 2007. | 6–15 months. | Inpatient | Not performed | Industry |
| Bouman 201121628721NetherlandsGenetic substudy of the Popular study | Prospective, observational, single-center cohort study | NO | Consecutive sampling (but then patients without DNA samples were excluded) | Patients with CAD taking clopidogrel undergoing elective coronary stent implantation and who were genotyped | December 2005 and December 2007 | Total 1 year | Inpatient/outpatient followup after intervention | Not performed | NR but authors received speakers fee from industry. (NB Popular study received platelet-testing equipment from industry) |
| Campo 201121679849ItalyNR | Prospective cohort | No | Consecutive | Patients undergoing PCI for ischemic heart disease who had a baseline and 1 month PRU evaluation and a baseline blood sample for genotyping | December 2008 to May 2009 | Max, 1 year | Inpatient followed by outpatient followup | Not performed | NR but authors have COIs with drug companies |
| Fernando 201121696537AustraliaNR | Prospective (randomized crossover study design) | NO | Unclear | Patients with ACS and stents on aspirin but not clopidogrel | NR | Duration for all patients who completed study, 14 weeks (6 weeks in each study arm with 2-wk washout in between) | Outpatient | YES80% | Non-industry only |
| Geisler 200818781853GermanyNR | Prospective pharmacogenetic trial  | NO | Consecutive | Caucasian patients undergoing PCI for CAD | July 2006-March 2007 | NR | Inpatient  | YES (86%) | NR except “The authors have no relevant financial involvement with any…entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes…grants…received or pending…” |
| Gladding 200819463375New ZealandPRINC (Plavix Response in Coronary Intervention) Trial | 2 by 2 factorial, randomized, placebo-controlled, double-blind study over the ﬁrst 24 h, followed by a 1-week randomized, placebo-controlled, double-blind study | NR | Sub study of RCT  | Patients undergoing elective PCI | NR | 7 Days total | Inpatient, with outpatient followup after the inpatient procedure | YES[YES (“~80%”)] | Non-industry(except VerifyNow analyzer was provided by Sanofi Aventis) |
| Gurbel 201019817997USANR | Prospective comparative? | NO | Unclear | Patients with stenting and stable condition who were screened for HPR | Feb. 1,-Sept. 15, 2008 | NR (max. follow-up, 7 to 10 days) | Outpatient | Not performed | All industry |
| Harmsze 201020833683NetherlandsNR | Retrospective case-control | YES | Consecutive enrollment  | Patients undergoing PCI with stenting | Cases: January 2004 to February 2007Controls: December 2005 and December 2006 | Total, 1 yr from the time of PCI | Hospital/outpatient | Not performed | Partly industry |
| Kim 201121511217South KoreaACCELAMI2C19High-dose clopidogrel | Randomized prospective  | NO | Sub study of RCT | 62 AMI patients treated with emergent PCI receiving a high-MD of clopidogrel | 2007-2009 | 30 days | Inpatient  | YES[YES] 80% | Partly industry |
| Kim 201121511217South KoreaACCELAMI2C19Cilostazol group | Randomized prospective | NO | Sub study of RCT | 64 AMI patients treated with emergent PCI receiving an adjunctive dose of cilostazol  | 2007-2009 | 30 days | Inpatient | YES[YES] 80% | Partly industry |
| Lee 201121786436South KoreaNR | Retrospective | NO | Selection of patients with testing for resistance and polymorphism | Patients with cerebrovascular disease who received clopidogrel and were tested for clopidogrel resistance and CYP2C19 polymorphism | January 2009 to June 2010 | NR | Outpatient | Not performed | Non-industry only |
| Malek 200818577829PolandNR | Prospective observational | Unclear | NR | Patients with any ACS undergoing PCI and receiving clopidogrel and aspirin | NR | 12 months | Inpatient and then outpatient followup (by phone) | Not performed | Non-industry only |
| Pettersen 201121426546NorwayAspirin and Clopidogrel non-responsiveness clinical Endpoint Trial (ASCET) | Prospective observational study | NO | Consecutively included randomized clopidogrel group from ASCET (n=219) | CAD patients randomized to receive maintenance clopidogrel (<80% PCI) | October 2005 to June 2008 | NR | Outpatient | Not performed | Non-industry only |
| Sibbing 201121527445GermanyNR | Prospective cohort | NO | For PCI cohort: volunteers for DNA sampling from prospective trial (1524/1608 [95%])For early ST cohort, consecutive recruitment and DNA sample availability | CAD patients undergoing PCI with stenting (>95%) and receiving clopidogrel and aspirin and who had DNA samples | For PCI cohort (who were the control cohort also), Feb 2007–April 2008 | NR | Inpatient | Not performed [ | Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”] |
| Sibbing 201121527445GermanyNR | Case-control | NO | Consecutive | CAD patients undergoing PCI with stenting | 1999-2008 | NR | Inpatient | Not performed  | Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”] |
| Simon 200919106083FranceFAST-MI | Prospective observational | YES | Consecutive | Patients with AMI in a French registry receiving clopidogrel | October 1–December 24, 2005 | Total 1 year | Inpatient (for the subgroup undergoing PCI); outpatient followup | Not performed | Partly industry |
| Hwang 201020823393KoreaACCEL-RESISTANCE, DM, COMPLEX(High-dose clopidogrel group) | Prospective cohortHwang  | No  | Sub study of RCT | High-risk CAD patients undergoing PCI | Jan 2008–June 2009 | 30 days | Inpatient  | Not performed | Non industry  |
| Hwang, 201020823393KoreaACCEL-RESISTANCE, DM, COMPLEX(Triple antiplatelet therapy group) | Prospective cohortHwang  | No | Sub study of RCT | High-risk CAD patients undergoing PCI | Jan 2008–June 2009 | 30 days | Inpatient | Not performed | Non industry |
| Bouman, 2011Multinational21170047NR | Case-cohort study | Yes | Random (for controls); incident cases (convenience because of refusals) | Patients with CAD undergoing PCI with stenting | 2003–2007  | 18 mo | Inpatient | Yes (but not for CYP2C19 variants) | No funding information; reported that the authors had no financial conflicts of interest |
| Bouman2011Multinational21170047NR | Prospective cohort | Yes | Convenience sample | Patients undergoing PCI with stenting | 2007–2009 | 12 months | Inpatient | Yes(80%) | No funding information; reported that the authors had no financial conflicts of interest |
| Price, 201222624833USGIFT (Genotype Information and Functional Testing) Study—a prespeciﬁed genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay–Impact on Thrombosis And Safety) trial | Genetic substudy of randomized, multicenter trial (GRAVITAS) | YES (all in North America) | Subsample of GRAVITAS patients—those with samples for genotyping and who were randomized to receive clopidogrel | Adults with CAD or ACS undergoing PCI with at least 1 DES, with or without high on-treatment platelet reactivity | July 2008–April 2010 | Total 6 mo | 48 Hospital centers | YES (YES: 80%) | All industry |
| Gremmel, 201222154242AustriaNR | Prospective observational | NO | NR | CAD patients undergoing stenting | Jan. 2008-Nov. 2010 | ~1 day (no followup time points) | Hospital (Medical University of Vienna, Division of Angiology) | NO (NA) | NR |
| Harmsze, 201222228204NetherlandsPOPular substudy | Genetic substudy of prospective POPular study but otherwise NR | YES | Consecutive (part of POPular) | CAD patients undergoing elective stenting | NR | 1 yr total | Hospital and then outpatient followup | NO (NA) | NR |
| Kreutz, 201222427735USNR | Observational | NO | NR | CAD patients receiving clopidogrel | NR | 1 day total | Hospital visit for measurements | NO (NA) | NR |
| Dai, 201222704413ChinaNR | Prospective observational | NO | NR | Patients undergoing PCI and stenting† | July 2009-April 2011 | 1 month | Hospital for intervention, outpatient measurement of reactivity at 10 days, and telephone contact with outpatients at 1 month | NO (NA) | NR |
| Cuisset, 201121803320FranceNR | Prospective cohort | no  | consecutive | NSTE ACS patients undergone PCI | July 2008- Jan 2010 | 1 month | inpatient | no  | NR |
| Chen. 201222723959TaiwanCAPTAIN | cohort study | no | registry  | CAD patients undergone PCI with stenting | Nov 1995-June 2011 | NR | inpatient | NR | non-industry |
| Gajos, 201222623230PolandOMEGA-PCI | RCT | no | consecutive | patients with stable CAD undergoing PCI | NR | 1 month | inpatients  | NR | NR |
| Luo, 201122118006ChinaNR | prospective cohort | no | consecutive | patients with stable CAD undergoing PCI | March 2006-May 2010 | 6 months | inpatients and then outpatients | NR | non-industry  |
| Tello-Montoliu 201222116003Spainstudy one of the paper | cohort for first objective | no | selective patients undergone PCI | stable ACS patients with stent  | NR | NR | outpatient clinic | NR | non-industry  |
| Tello-Montoliu 201122116003SpainSecond objective | cohort for second objective | no | consecutive | non-ST elevation acute coronary syndrome  | NR | 6 months | inpatient | NR | non-industry  |
| Harmsze, 201121854540NetherlandsNR  | prospective | no | consecutive | CAD for PCI | NR | 1 year  | inpatient  | NR | industry |
| Ono, 201121862109JapanNR | NR | No | consecutive | CAD for PCI | Oct 2008-Nov 2010 | 12 months | inpatients then follow up | NR | non-industry  |
| Delaney, 201222190063USANR | NR | NR | BioVU database | patients started clopidogrel after an MI and/or PCI with stent placement | NR-June 2011 | 2 years | Vanderbilt DNA biobank | NR | non-industry  |
| Bhatt, 201222450429USACHARISMA | subset of RCT | yes | RCT | patient on clopidogrel for high atherothrombotic risk and ischemic stabilization | NR | 800 days | NR | NR | industry  |
| Fontana 2011 21692977SwitzerlandADRIE | prospective cohort | yes | consecutive | ischemic atherothrombotic disease (CAD, ICD, PAD) | June 2006-Dec 2008 | 3 years | inpatient | NR | non-industry  |
| Aleil, 200919624462FranceVASP-02 [genetic reanalysis thereof] | Genetic posthoc analysis of RCT (nonblinded) | YES | NR | Adults without ACS undergoing elective stenting | April 2005-Dec. 2007 | Total 1 mo | Inpatient | NO (NA) | Partly industry |
| Chen, 201222071359ChinaNR | Prospective observational | NO | Consecutive | Adults with CAD  | July 2008-Sept. 2009 | Mean 11.42 mo | Inpatient for angiography, outpatient thereafter | NO (NA) | Nonindustry |
| Kreutz, 201222385219USANR | Prospective observational | NO | NR | Adults with stable CAD | NR | 15 days | Outpatient | NO (NA) | Nonindustry |
| Marcucci, 201222390861ItalyNR | Prospective observational | NO | NR | Adults undergoing PCI and stenting for ACS | NR | 12 mo | Inpatient | NO (NA) | Nonindustry |
| Nishio, 201222785462JapanNR | Prospective observational | NO | NR | Patients undergoing PCI with DES stenting | June 2008-June 2010 | Mean 646.2 days, median 692.5 days | Inpatient | NO (NA) | NR |
| Park, 201222507978KoreaACCEL-STATIN | RCT (patients enrolled already having received clopidogrel and already ascertained as having HPR; randomization was for pravastatin or rosuvastatin) | NO | “Prospective” | Adults with HPR having had a PCI with >=6 mo of antiplatelet therapy | April 2009-Dec. 2011 | 15 day total | Inpatient | YES (YES) | Nonindustry (article says “partly funded” by nonindustry and does not mention industry) |
| Teixeira, 201222377481PortugalNR | Prospective observational | NO | NR | Patients <75 yr admitted for ACS and survived | March [or April—one stated in one place and one another place]-Oct 2009 | Median 136.0 days after discharge | Inpatient | NO (NA) | NR |
| Parri, 201222727972ItalyNR | RCT (with randomization only to pantoprazole or ranitidine) | NO | NR | Patients with STEMI and undergoing PCI | July 2009-Feb 2010 | 30 days total | Inpatient | YES (YES) | NR |
| Yamane, 201222472213JapanNR | cohort study | no | NR | patients with prior coronary stent implantation who had received dural anti-platelet therapy  | Sep 2009 and May 2011 | ≥ 4 weeks | inpatient  | yes (<80%) | non-industry  |
| Hsu, 201121144850TaiwanNR | open label RCT  | no | consecutive | atherosclerotic disease such as ischemic heart disease or stroke  | Aug 2008 to Jan 2010 | 6 months | inpatient  | yes (90%) | non-industry  |
| Kim, 2012 22007612KoreaACCEL-TRIPLE | prospective cohort | no | NR | PCI treated patients | Jan 2008–June 2009 | 1 months  | inpatients | yes (90%) | non-industry  |
| Siller-Matula, 201222260716AustriaPEGASUS-PCI | prospective cohort | no | consecutive | patients undergoing PCI | March 2007–Nov 2009 | 12 months | inpatient and then followup | yes, 80% | Austrian National Bank |
| Bonello, 201222285300FranceNR | prospective | yes | NR | PCI for non-ST elevation Acute Coronary Syndrome (NSTE ACS) | January 2010–September 2011 | 6-12 hours after clopidogrel loading dose | Inpatient  | No | Non-industry (Research grant from the Assistance Publique - Hopitaux de Marseille) |
| Simon, 201121918510FranceFAST-MI | Prospective observational study (registry-based) | Yes  | Consecutive | All AMI patients (and a subset of AMI patients undergoing PCI)  | November 2005 | 1 year  | Inpatient (from ICU) and then outpatient followup  | No | Partly industry |
| Collet, 201121511218FranceCLOVIS-2 | RCT-Crossover trial  | NR | Selected sample (from a registry) | Patients who had survived an MI before age 45 | NR | 6 hours (between baseline and measurement of platelet reactivity) | Inpatient  | Yes; >80% of target | Non-industry only |
| Jaitner, 201222298798GermanyNR | Cases from a registry and controls from a prospective cohort  | No | Cases from a registry with a DES thrombosis & event free patients from a cohort of subjects undergoing PCI for CAD | CAD patients undergoing PCI with stenting | For PCI cohort (who were the control cohort also), Feb 2007–April 2008Cases: 1999–2008 | NR | Inpatient | No | Non-industry only  |
| Mega, 201122088980USAELEVATE-TIMI 56 | RCT | Yes | Consecutive | CAD patients on clopidogrel | October 2010–September 2011 | 2 weeks | Outpatient | Yes; >80% of target | Industry |
| Hochholzer, 201121884870NREXCELSIOR | Prospective cohort | NR | NR | CAD patients undergoing PCI with stenting | NR | 24 hours | Inpatient | No | NR |
| Kassimis, 201221831410GreeceNR | Prospective  | No | Consecutive | CAD patients undergoing PCI with stenting | NR | 24 hours | Inpatient | No | NR |
| Namazi, 201222265638IranNR | Prospective | No | NR | CAD patients undergoing PCI with stenting | September 2007–October 2008 | 30 days | Inpatient and then outpatient | No | Non-industry only |
| Rideg, 201121806387HungaryDOSER | Substudy of RCT | No | consecutive | CAD stable angina patients undergoing PCI with stenting | February 2008–September 2009 | 1 year | Inpatient and then outpatient | No | Non-industry only |
| Jeong, 201122045970KoreaNR | Prospective | No | selected sample | AMI patients who underwent angiography | September 2007–August 2009 | 1 year | Inpatient and then outpatient | yes (accrual >80%) | Non-industry only |
| Chan,201222462746SingaporeNR | Prospective | No | selected sample | CAD patients undergoing PCI or angiography | NR | 7 days | Inpatient; followup after intervention | No | Industry and Non-industry  |
| Goodman, 201222261200Multi-countryPLATO | Clopidogrel arm of an RCT | Yes | consecutive | ACS patients undergoing PCI | NR | 1 year | Inpatient and then outpatient | No | Industry only |
| Park, 201222735685KoreaCROSS-VERIFY | Prospective | No | consecutive | CAD patients undergoing PCI | June 2006–June 2010 | 12 months | Inpatient and then outpatient | No | Non-industry only |
| Kreutz, 201222459907USANR | Prospective | No | Selected sample | CAD patients undergoing PCI | NR | 16-24 hours | Inpatient  | No | Non-industry only |
| Yan, 201121778720ChinaNR | Prospective | No | Consecutive | ACS patients undergoing PCI  | NR | 24 months (NR in text, seen in Fig 1) | Inpatient and then outpatient | No | Non-industry only |
| Jeong, 201222837373KoreaACCEL-DM | prospective cohort | no | selected sample | type 2 diabetes undergoing PCI | NR | 30 days | inpatient then followup | yes (90%) | NR |
| Cayla, 201122028352FranceONASSIST | case-control study | Yes | Consecutive | Patients undergoing PCI with stenting | January 2007–May 2010 | NR | Inpatient | Yes | Industry and on-industry grants |
| Hulot, 201121972404FranceAFIJI | prospective cohort | Yes | Convenience sample | AMI before age 45 | NR | 2.6 yr (median clopidogrel exposure time) | NR | no | Non-industry only |
| Hulot, 201121972404 FranceCLOVIS-2 | prospective cohort | Unclear | Substudy of RCT | AMI before age 45 | NR–April 2008 | 6 hours | inpatient | No | Non-industry only |
| Roberts, 201222464343CanadaRAPID GENE | RCT | no | NR | NSTE-ACS or chronic CAD undergoing PCI with stenting | August 2010–July 2011 | 30 days | inpatient | yes | Industry and on-industry grants |

**Abbreviations:** ACS = acute coronary syndrome; AMI = acute MI; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, IV=Intravenous; LD=Loading dose; MD=Maintenance dose; MI = myocardial infarction; NR=Not reported; NSTE = non-ST-elevation;NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; RCT=randomized controlled trials; STEMI = ST-elevation MI; TIA = transient ischemic attack; UFH=Unfractionated Heparin; ICD, ischemic cerebrovascular disease.
†Patients were selected for “blood stasis syndrome” (a diagnosis in traditional Chinese medicine) but also for having undergone PCI with stent placement. Because patients were only eligible if they had undergone PCI and were enrolled after PCI, the study was included.